Establishment of a Pharmaceutical Production Plant in Anjo and Reorganization of Medical Production Sites
First written in FY2016. 7 of 12 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2022-Q3.
The whole theme swung hardest in 2025: 1 of 6 companies on the "Worse" side.
2 other companies' latest entry also says "Restated".
- FY2022-Q3RestatedAnnual report
「Property, plant and equipment increased by ¥851 million. The increase was attributable mainly to an increase in construction in progress resulting from investment by ニチバンメディカル in medical-device manufacturing equipment and other assets.」
Investment in medical-device manufacturing equipment and other assets and the resulting increase in construction in progress at the Medical production bases are continuing. - FY2022-Q2AdvancedAnnual report
「In addition, the increase in property, plant and equipment was attributable mainly to an increase in construction in progress resulting from investment by ニチバンメディカル in medical-device manufacturing equipment and other assets.」
For the Medical production bases, construction in progress increased as a result of investment in medical-device manufacturing equipment and other assets, indicating that site development is advancing. - FY2022-Q1AdvancedAnnual report
「The increase in property, plant and equipment was attributable mainly to an increase in construction in progress resulting from investment by ニチバンメディカル in medical-device manufacturing equipment and other assets.」
For the Medical production bases, the company reported investment in medical-device manufacturing equipment and other assets, together with an increase in construction in progress, indicating that site development is continuing. - FY2019AdvancedAnnual report
「We will expand production at the Medical Anjo Plant, which was completed in January 2018, and continue delivering products of more reliable quality.」
Following completion of the plant and relocation of the Osaka plant, the company identified expanding production at the Medical Anjo Plant as its next operational priority. - FY2019-Q3AdvancedAnnual report
「Despite higher revenue, operating profit fell 27.9% year on year to ¥2,862 million due to higher depreciation expense associated with the start-up of the new plant, increased cost of sales resulting from higher raw material prices and energy costs, and a temporary increase in selling, general and administrative expenses.」
The new Anjo plant was in the start-up phase following completion and relocation, and the increase in depreciation expense affected operating profit. - FY2018AchievedAnnual report
「January 2018 Advanced Technology Building completed, Osaka plant relocated Name changed to Medical Anjo Plant」
The Advanced Technology Building in Anjo was completed in January 2018, followed by the relocation of the Osaka plant and the name change to Medical Anjo Plant. - FY2018-Q3Loss related to construction recordedAnnual report
「Loss related to construction of new plant - 74」
A ¥74 million loss related to construction of the new plant was recorded as an extraordinary loss. No completion of the new plant was reported. - FY2018-Q2AdvancedAnnual report
「Construction in progress 4,768 6,248」
Construction in progress increased from ¥4,768 million at the end of the previous consolidated fiscal year to ¥6,248 million. A ¥16 million loss related to construction of the new plant was also recorded, but no statement was made regarding completion. - FY2017AdvancedAnnual report
「Anjo site—Advanced Technology Building Pharmaceutical production plant and research facility 8,000 2,289 Internal funds June 2016 January 2018」
The planned investment of ¥8,000 million and scheduled completion in January 2018 for the Anjo site were maintained, while the amount already paid rose to ¥2,289 million. - FY2017-Q3AdvancedAnnual report
「8,000 2,211 Internal funds June 2016 January 2018」
For the pharmaceutical production plant and research facility at the Anjo site, the planned investment of ¥8,000 million and scheduled completion in January 2018 were maintained, while the amount already paid increased from the previously reported ¥1,868 million to ¥2,211 million. - FY2017-Q2RaisedAnnual report
「We have changed the planned investment amount from ¥6.0 billion to ¥8.0 billion to establish future production capacity in response to strong performance of medical business products.」
The planned investment in the pharmaceutical production plant and research facility at the Anjo site was increased from ¥6,000 million to ¥8,000 million. The amount already paid was ¥1,868 million, while the scheduled completion date remained January 2018. - FY2016First statedAnnual report
「Pharmaceutical production plant and research facility」
The company plans to build a pharmaceutical production plant and research facility in Anjo City with a planned investment of ¥6,000 million, beginning work in June 2016 and scheduled for completion in January 2018. The project aims to establish an optimal production system by reorganizing production functions between the new plant and ニチバンメディカル.